top of page

GRYPHON BIO

Diagnostic-Powered Therapeutics for Brain Health

Home: Welcome

OUR STORY

Gryphon Bio is an early-stage company created to harness our co-founders' discovery of unexpected waves of 1000s of brain molecules in the blood as novel therapeutic targets and temporal blood biomarkers (brain-specific proteins with blood levels that change over time like waves in the ocean). They made these discoveries over more than 20 years of “brain proteomic” research, the large-scale measurement of proteins in the brain. 

Mission: To develop and market the first diagnostic-powered therapeutics for brain health.


Vision: To pioneer diagnostic-powered therapeutics to improve the lives of patients.

Home: About Us

OUR PIPELINE

Diagnostic-Powered Therapeutics

We are researching a promising, diversified pipeline of large molecule medicines, known as biologics, by following clues from nature’s sequence of cellular and molecular events for CNS repair. Each biologic has a unique mechanism(s) of action (MOA) and pharmacokinetic/pharmacodynamic (PK/PD) profile, compelling biology, and binds to a novel or de-risked therapeutic target(s).


Development of these and other diagnostic-powered therapeutics will be performed by a wholly owned subsidiary of Gryphon Bio: Owl Therapeutics.

Brain Health

Virtual clinical trials, where blood specimens and cognitive assessments can be collected both in the hospital and at home or in the field, guide the development of our temporal CNS blood biomarkers and biologics. In the future, we envision close engagement with our patient communities to assess needs and to develop artificial intelligence-based telemedicine solutions for brain health.

Diagnostics

Novel blood tests based on temporal CNS blood biomarkers should improve the care, management, and hospitalization of our courageous patients. Potential indications of use should include screening for disease, predicting outcome, monitoring patients’ disease progression, and phenotyping individual trajectories to reconstruct and inform on key decisions (e.g., recovery, hospitalization, and return-to-work). Our novel blood tests should also improve the likelihood of regulatory approval of our biologics by health authorities. 

Child at the Doctor
Home: Portfolio

OUR COURAGEOUS PATIENTS

CNS diseases are leading causes of death and disability, including:

Brain Scans
  • Traumatic brain injury (TBI)

  • Alzheimer's disease (AD)

  • Neonatal Encephalopathy (NE)

  • Post-traumatic epilepsy (PTE)

  • Alexander's disease (AxD)

  • Alzheimer's disease related dementias (ADRD)

  • Multiple sclerosis (MS)

  • Brain metastatic breast cancer (bmBC)

  • Chronic traumatic encephalopathy (CTE)

  • Frontotemporal degeneration (FTD)

  • Spinal cord injury (SCI)

  • COVID-19

Home: Patients

OUR INVESTORS

$13M

Non-Dilutive Funding (Grant Awards & Contracts)

$0.65M

Total Cash Raised

Home: Infographics

OUR COURAGEOUS TEAM

We are a proven, cohesive, interdisciplinary and internationally recognized team with deep experience in drug development (e.g., therapeutic bioconjugates), business development (e.g., licensing, intellectual property and partnerships) and CNS biomarker development (e.g., TBI). Together with our advisors, we have 1000+ previous peer-reviewed publications and $100M+ in previous grant awards. Moreover, we have successfully led several preclinical and clinical studies on successful high impact assets in industry and academe.

If you want to learn more about our amazing team members, get in touch.

Home: Our Team
Will Haskins

WILL HASKINS, PHD

CEO & Co-Founder

Dr. William E. Haskins, Ph.D. (Co-Founder and CEO) in collaboration with Drs. Wang and Forsthuber, discovered unexpected waves of brain molecules in the blood as temporal biomarkers and therapeutic targets. He previously led teams for R&D of gene therapies, therapeutic antibody, and antibody-drug conjugates from Research through Phase I/II/III clinical trials for small and large biotechnology companies, including Genentech. Dr. Haskins is well-respected for developing and applying out-of-the-box solutions to challenging problems. He is highly experienced with analytical and bioanalytical chemistry, proteomics, bioinformatics, CNS biomarkers, and large molecule drug development (OCREVUS®, KADCYLA®, POLIVY®, etc.). He has authored or co-authored more than 73 peer-reviewed publications and numerous patents, and he is the Principal Investigator for several federal grant awards. Lastly, Dr. Haskins completed postdoctoral fellowships at the McKnight Brain Institute and Lawrence Livermore National Laboratories after earning his PhD in Bioanalytical Chemistry from the University of Florida in 2003.

Microscope

OUR LATEST NEWS

What's New

Home: News

Check our news section on a regular basis to always stay in the loop.

cdmrp_.jfif

13. GRYPHON BIO RECEIVES NEW DOD GRANT AWARD TO ADVANCE CRITICAL RESEARCH IN POST-TRAUMATIC EPILEPSY

October 29, 2023

South San Francisco, CA – Sunday, July 1, 2023– Gryphon Bio, Inc. and Citizens United for Research in Epilepsy (CURE), together with Cambridge University, Morehouse School of Medicine, and Mario Negri Institute for Pharmacological Research IRCCS (IRFMN), were awarded more than $1.2M in Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP)-funding for its Epilepsy Research Program (ERP)-sponsored research multi-year grant award entitled “Temporal Dynamics of Astrocytic Activation and Function in Post-Traumatic Epilepsy (PTE) Genesis and Progression”. Background: Post-traumatic epilepsy (PTE) is when someone experiences recurring and unprovoked seizures after sustaining a traumatic brain injury (TBI). PTE is a common and serious complication of TBI. There are no FDA-approved medicines for prevention or treatment of PTE beyond current antiepileptic drugs, and there are no blood tests based on biomarkers for PTE. The disease course from TBI to PTE is not well understood, which further hampers the development of novel biomarkers and therapeutic targets. This project aims to identify specific changes in astrocytes, which are special star-shaped cells in the central nervous system, and how they contribute to the transition from TBI to PTE. Based on evidence we gathered in our previously funded DoD grant, which revealed molecules associated with astrocytes are activated in mice with PTE, compared to mice without PTE, we believe that astrocyte signatures have a key role in the progression from TBI to PTE. We think that by clarifying how these signatures impact TBI/PTE, we can identify novel PTE-associated molecules for future blood tests and therapeutics for PTE. We will do this by integrating various neuroimaging and large-scale molecular analyses to characterize the temporal dynamics of astrocytic signatures both before and after PTE starts, in a mouse model and in patient samples.  According to Gryphon Bio CEO and Principal Investigator Will Haskins, “This grant award provides essential funding for improving our understanding of the molecular mechanisms of astrocytes in TBI and PTE patients.”

OUR LOCATIONS

CA.jpg

611 GATEWAY BLVD. SUITE 120 #253
SOUTH SAN FRANCISCO, CA 94080

TX.jpg

200 EAST GRAYSON ST. SUITE 101
SAN ANTONIO, TX 78215

Home: List
bottom of page